Ratio Therapeutics Secures $50 Million Series B Financing to Advance Targeted Radiopharmaceuticals for Solid Tumors

Jan 17, 2024 23:10 CST Updated 23:10

Ratio Therapeutics

Targeted Radiopharmaceuticals Developer

Pagsgroup

Early-Stage Investment Fund

Bristol-Myers Squibb

Biopharmaceutical and Nutritional Product R&D and Sales

January 17, Boston, Ratio Therapeutics, a pharmaceutical company utilizing a range of innovative technologies to develop optimal radiopharmaceuticals for the treatment and monitoring of cancer, announced the completion of a $50 million Series B financing round, bringing the total amount of funds raised to date to over $90 million. The latest round of financing saw continued participation from Series A investors Schusterman and Duquesne, and was supported by PagsGroup, Bristol-Myers Squibb, and Cornell University Technology Licensing, among others.New Frontier! Over $20 Million in Seed Funding to Develop Radiopharmaceuticals）

Financing will expand the company's proprietary technology platforms Trillium™ and Macropa™.Application`, develop novel best-in-class purpose-suited radiopharmaceuticals. Additionally, this funding will advance the clinical development of the company's fibroblast activation protein alpha (FAP)-targeted radiopharmaceutical therapy.`

Jack Hoppin, Ph.D., Chairman and Chief Executive Officer of Ratio Therapeutics, Inc., said:"This funding advances Ratio's technology platform and will help initiate clinical trials of our FAP-targeted radiotherapy, which aims to treat a range of solid tumor cancers. We appreciate the investors' confidence in our technology. We have submitted two INDs and completed enrollment for two radiation dosimetry studies to support our two corporate partnerships. Now we have the backing to advance our first therapeutic candidate into clinical trials by the end of this year."

Ratio's radiopharmaceutical strategy focuses on optimizing tumor targeting while minimizing uptake by normal tissues. To achieve this goal, the company utilizes its proprietary platform namedTrillium™The proprietary technology platform, which is based on Dr. Babich's prior research at Weill Cornell Medicine and was initially developed and validated by the founders in a previous venture. Trillium is a trifunctional small molecule scaffold that can be fine-tuned to alter its plasma clearance, target affinity, and therapeutic payload. Each component of the scaffold can be independently optimized to enhance tumor uptake over normal tissue uptake, thereby maximizing the therapeutic index. Ratio has successfully applied this framework to multiple tumor targets and various therapeutic payloads.

In addition, Ratio is developing a technology platform to harness the tumor-killing potential of the α-emitter Actinium-225. This proprietary technology is calledMacropa™ Chelation PlatformThe scientists at Ratio have successfullyMacropa™And several peptides and antibodies integrated intoTrillium™In the platform.Macropa™The unique chemical composition makes the resulting radiotherapeutic compounds easy to manufacture and highly stable both in vitro and in vivo.

Follow the official account below to see the world!